Wave culls leading Huntington's meds as shares go under after rival Roche hit by similar fate

Wave culls leading Huntington's meds as shares go under after rival Roche hit by similar fate

Source: 
Fierce Biotech
snippet: 

Just over a year after Wave Life Sciences cut staffers, threw out a Duchenne muscular dystrophy med and saw its Huntington's disease drug flop in a key test, the waves come crashing down again for the biotech.


In an update posted after-hours Monday evening, Wave said data out of a midstage tests for two of its Huntington’s drugs, WVE-120102 and WVE-120101, were simply too poor to keep going, and they have been axed.